Study Reveals Promising Data on Nilotinib as a Therapy for Diffuse Systemic Sclerosis. Nilotinib was generally well-tolerated by systemic sclerosis patients, with tolerability being primarily limited by mild cardiovascular side effects. Scleroderma News, 08/24/2015. (Also see Clinical trials)
Study Finds Cell Microparticles Correlated with Lung Function in Systemic Sclerosis (SSc) Patients. Investigating microparticles further may help to better understand the pathogenesis of disease and enhance disease activity monitoring in patients with SSc. Scleroderma News, 08/17/2015. (Also see Endothelin and Systemic Scleroderma)
Human Stem Cell Transplantation (HSCT) Revealed As Promising Treatment For Systemic Sclerosis. The HSCT method appears to be a promising treatment of systemic sclerosis disease and the results of this study demonstrate substantial improvement over the course of 12 months treatment. Scleroderma News, 08/20/2015. (Also see Clinical Trials)
Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement (GI) in systemic sclerosis (SSc). Sustained benefit from IVIG suggests a specific immunomodulatory effect on those with established SSc GI complications. PubMed, Rheumatology (Oxford), 08/28/2015. (Also see IVIg and Gastrointestinal Involvement)
Pleural irregularity (PI), a new ultrasound sign for the study of interstitial lung disease(ILD) in systemic sclerosis (SSC) and antisynthetase syndrome (ASS). PI is useful for evaluation of ILD in SSc and ASS patients and can be incorporated into a diagnostic algorithm in SSc patients to reducing the need for exposure to ionising radiation. PubMed, Clin Exp Rheumatol, 08/27/2015. (Also see Pulmonary Fibrosis)
T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. T helper 17 cell immune polarization in patients with PAH has been highlighted, as has been previously demonstrated in other chronic inflammatory and autoimmune conditions. Chest, 2015;147(6):1610-1620. (Also see Pulmonary Hypertension Research)
Iloprost Found To Mitigate Raynaud’s Syndrome Symptoms and Heal Associated Digital Ulcers. Iloprost is a safe and effective therapy for secondary Raynaud’s syndrome as it can ease the disease’s symptoms, improve the disability grade and heal or prevent the development of digital ulcers. Scleroderma News, 08/14/2015. (Also see Raynaud's Treatments: Medications and Treatments for Digital Ulcers)
New Potential Serum Biomarker for Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis. The research team concluded that CC16 serum levels can be considered a potential biomarker for ILD in systemic sclerosis patients. Scleroderma News, 08/12/2015. (Also see Pulmonary Fibrosis Diagnosis)
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. These data provide further evidence of B-cell involvement in the pathogenesis of scleroderma and targeting B cells may be a promising treatment for scleroderma patients. PubMed, Clin Exp Rheumatol, 2015 Sep-Oct;33 Suppl 91(4):160-167. (Also see B Cells and T Cells and Clinical Trials)
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.